The COVID-19 pandemic taught us many lessons, but we have yet to fully implement our collective learnings. As the virus hit, vaccines were developed at speed, yet societies across the world still lacked therapeutic tools that could be rapidly and sustainably scaled at a global level. Small molecule antivirals are essential in order to beat the next pandemic, reducing morbidity and mortality and slowing the development and transmission of new variants escaping vaccines and neutralizing antibodies. In support of the G7’s recommended 100 Days Mission and the International Pandemic Preparedness Secretariat (IPPS), the INTREPID Alliance this year began publishing quarterly global landscape assessments of antiviral compound R&D. These reports seek to aid in the identification of clinical (e.g., Phase 2/3 ready) and preclinical antivirals aligned with the 100 Days Mission and highlight gaps in the pipeline, to support the goal of developing at least two ‘Phase 2 ready’ therapeutic candidates against the identified viral pathogen families of greatest pandemic potential. In this session we seek to bring together voices from across the global public and private R&D and funding ecosystem to identify the barriers to success. What can be done from within the biotech ecosystem today, to ensure that we aren’t left unprepared to treat the next pandemic tomorrow.